β-funaltrexamine (β-FNA) and neural tumor response in mice

I. S. Zagon, P. J. McLaughlin, A. E. Takemori, P. S. Portoghese

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The effects of β-FNA, a highly selective and irreversible μ opioid receptor antagonist, in altering tumor response in A/Jax mice inoculated with S20Y cells were determined. Inoculation of neuroblastoma cells in control subjects resulted in 100% tumor incidence within 16 days, and mean median survival times of 36 and 35 days, respectively, following tumor inoculation. Tumor incidence and survival times were comparable to controls for mice given chronic injections of 2 mg/kg and 10 mg/kg β-FNA every 48 h beginning 2 days after tumor inoculation. Tumor growth was subnormal in the 10 mg/kg β-FNA group. Both dosages of β-FNA were found to block morphine-induced analgesia for 48 h. These results suggests that, in and by themselves, μ receptors selectively antagonized by β-FNA do not play an important role in neuro-oncogenic events.

Original languageEnglish (US)
Pages (from-to)165-169
Number of pages5
JournalEuropean Journal of Pharmacology
Volume116
Issue number1-2
DOIs
StatePublished - Oct 8 1985

Bibliographical note

Funding Information:
This research was supported in part by NIH Grants NS-20623, NS-20500 and NS-01533.

Keywords

  • Endogenous opioids
  • Mice Cancer β-Funaltrexamine
  • Neuroblastoma
  • Opioid receptors
  • Tumor biology

Fingerprint

Dive into the research topics of 'β-funaltrexamine (β-FNA) and neural tumor response in mice'. Together they form a unique fingerprint.

Cite this